Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Feifel

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Psychiatry|March 6, 2025
Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive DisorderGuy M Goodwin, Ania Nowakowska, Merve Atli, et al.
JCI Insight|January 24, 2023
Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMSAbraham Zangen, Samuel Zibman, Aron Tendler, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 10, 2021
Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trialAbraham Zangen, Hagar Moshe, Diana Martinez, et al.
Journal of Affective Disorders|May 17, 2026
Interdisciplinary, delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American society of ketamine physicians, psychotherapists, and practitioners (ASKP3)David S Mathai, Madeleine Cluck, Amna M Aslam, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|January 5, 2025
Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical NeurophysiologyNicholas T Trapp, Anthony Purgianto, Joseph J Taylor, et al.
Biological Psychiatry|July 18, 2021
Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized TrialMoshe Isserles, Aron Tendler, Yiftach Roth, et al.
Journal of Affective Disorders|March 25, 2026
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Brain Stimulation|July 6, 2015
Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major DepressionAndrew F Leuchter, Ian A Cook, David Feifel, et al.
Journal of Affective Disorders|December 20, 2024
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|October 11, 2025
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Psychiatry|March 6, 2025
Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive DisorderGuy M Goodwin, Ania Nowakowska, Merve Atli, et al.
JCI Insight|January 24, 2023
Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMSAbraham Zangen, Samuel Zibman, Aron Tendler, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 10, 2021
Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trialAbraham Zangen, Hagar Moshe, Diana Martinez, et al.
Journal of Affective Disorders|May 17, 2026
Interdisciplinary, delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American society of ketamine physicians, psychotherapists, and practitioners (ASKP3)David S Mathai, Madeleine Cluck, Amna M Aslam, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|January 5, 2025
Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical NeurophysiologyNicholas T Trapp, Anthony Purgianto, Joseph J Taylor, et al.
Biological Psychiatry|July 18, 2021
Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized TrialMoshe Isserles, Aron Tendler, Yiftach Roth, et al.
Journal of Affective Disorders|March 25, 2026
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Brain Stimulation|July 6, 2015
Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major DepressionAndrew F Leuchter, Ian A Cook, David Feifel, et al.
Journal of Affective Disorders|December 20, 2024
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|October 11, 2025
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Pageof 12